Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026)

Sarepta Therapeutics has reported Common Equity for 17 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 31.71% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 31.71% YoY), and the FY2025 full-year result was $1.1 billion, down 25.34% from the prior year.
• Common Equity for Q1 2026 stood at $1.5 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Common Equity was $1.5 billion in Q4 2024, with the low at $385.0 million in Q4 2022.
• Average Common Equity over 5 years is $984.1 million, with a median of $961.2 million recorded in 2024.
• Year-over-year, Common Equity sank 58.52% in 2022 and jumped 123.23% in 2023.
• Tracing SRPT's Common Equity over 5 years: stood at $385.0 million in 2022, then soared by 123.23% to $859.3 million in 2023, then jumped by 77.78% to $1.5 billion in 2024, then decreased by 25.34% to $1.1 billion in 2025, then surged by 31.95% to $1.5 billion in 2026.
• The last three Common Equity figures came in at $1.5 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison